科华生物
(002022)
| 流通市值：30.80亿 | | | 总市值：30.81亿 |
| 流通股本：5.14亿 | | | 总股本：5.14亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,191,260,566.76 | 793,574,870.31 | 387,883,698.3 | 1,759,197,330.48 |
| 营业收入 | 1,191,260,566.76 | 793,574,870.31 | 387,883,698.3 | 1,759,197,330.48 |
| 二、营业总成本 | 1,395,129,544.97 | 907,300,284.93 | 443,013,698.68 | 2,114,186,830.03 |
| 营业成本 | 764,646,192.49 | 496,885,326.02 | 242,858,484.69 | 1,111,972,861.71 |
| 税金及附加 | 8,147,903.74 | 5,424,225.38 | 2,642,065.74 | 11,908,612.56 |
| 销售费用 | 268,506,204.17 | 183,936,650.64 | 80,216,690.04 | 433,903,054.3 |
| 管理费用 | 228,697,454.09 | 143,017,855.95 | 70,478,985.28 | 335,947,424.2 |
| 研发费用 | 114,226,587.57 | 73,631,500.57 | 44,061,435.78 | 198,666,101.37 |
| 财务费用 | 10,905,202.91 | 4,404,726.37 | 2,756,037.15 | 21,788,775.89 |
| 其中:利息费用 | 19,271,096.52 | 12,178,726.7 | 5,880,332.97 | 42,229,223.95 |
| 其中:利息收入 | 5,093,554.87 | 3,498,867.99 | 1,693,307.75 | 21,458,947.33 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 13,984.75 | -19,103.55 | -15,081.75 | -1,172,720.33 |
| 加:投资收益 | 1,056,127.82 | 715,257.64 | 252,555.56 | 11,973,131.52 |
| 资产处置收益 | 2,631,988.46 | 2,344,755.76 | 1,077,766.1 | 4,208,562.56 |
| 资产减值损失(新) | -35,199,092.61 | -21,392,766.4 | 881,045.4 | -225,183,072.01 |
| 信用减值损失(新) | -27,534,853.98 | -11,004,933.29 | -4,970,053.18 | -193,754,338.37 |
| 其他收益 | 12,168,202.69 | 7,650,284.85 | 3,886,665.22 | 32,094,361.72 |
| 四、营业利润 | -250,732,621.08 | -135,431,919.61 | -54,017,103.03 | -726,823,574.46 |
| 加:营业外收入 | 1,623,340.76 | 757,194.23 | 65,383.9 | 830,799.12 |
| 减:营业外支出 | 2,644,494.26 | 1,062,573.1 | 335,200.44 | 8,852,873.59 |
| 五、利润总额 | -251,753,774.58 | -135,737,298.48 | -54,286,919.57 | -734,845,648.93 |
| 减:所得税费用 | 2,066,196.37 | 4,379,386.86 | -541,447.6 | -4,198,282.15 |
| 六、净利润 | -253,819,970.95 | -140,116,685.34 | -53,745,471.97 | -730,647,366.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -253,819,970.95 | -140,116,685.34 | -53,745,471.97 | -730,647,366.78 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -232,532,785.65 | -133,452,683.41 | -53,259,784.78 | -640,601,876.82 |
| 少数股东损益 | -21,287,185.3 | -6,664,001.93 | -485,687.19 | -90,045,489.96 |
| 扣除非经常损益后的净利润 | -242,590,731.29 | -139,851,547 | -56,636,264.18 | -668,720,852.88 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.45 | -0.26 | -0.1 | -1.27 |
| (二)稀释每股收益 | -0.45 | -0.26 | -0.1 | -1.27 |
| 八、其他综合收益 | 25,828,113.66 | 29,352,996.43 | 11,909,175.59 | -20,195,797.3 |
| 归属于母公司股东的其他综合收益 | 25,828,164.64 | 29,356,162.58 | 11,908,462.46 | -17,044,969.05 |
| 九、综合收益总额 | -227,991,857.29 | -110,763,688.91 | -41,836,296.38 | -750,843,164.08 |
| 归属于母公司股东的综合收益总额 | -206,704,621.01 | -104,096,520.83 | -41,351,322.32 | -657,646,845.87 |
| 归属于少数股东的综合收益总额 | -21,287,236.28 | -6,667,168.08 | -484,974.06 | -93,196,318.21 |
| 公告日期 | 2025-10-30 | 2025-08-27 | 2025-04-30 | 2025-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |